Literature DB >> 2562839

Dimeric dermorphin analogues as mu-receptor probes on rat brain membranes. Correlation between central mu-receptor potency and suppression of gastric acid secretion.

L H Lazarus1, A Guglietta, W E Wilson, B J Irons, R de Castiglione.   

Abstract

The opioid receptor preference for dermorphin and several dimerized structural analogues was investigated using rat brain synaptosomes and correlated with the potencies of intracerebroventricularly administered dimeric dermorphin peptides to inhibit gastric acid secretion. The carboxyl terminus of dermorphin or amino-terminal dermorphin analogues was bridged by dihydrazide or (poly)ethylenediamine structures. Synaptosomal membranes were prepared for radioligand binding assay in the presence of soybean trypsin inhibitor and preincubated to remove endogenously bound opioid peptides before storage at -70 degrees C. Specific radiolabeled agonists used in the radioligand binding assays were [D-Ala2,N-methyl-Phe4,Gly-ol5] [3H] enkephalin for mu-receptors and [D-Ala2,D-Leu5] [3H]enkephalin for delta-receptors. delta-Receptor binding assays were conducted in the presence of 2.6 microM [N-Me-Phe3,D-Pro4]morphiceptin to suppress peptide binding to mu-receptors. [D-Ala2,N-methyl-Phe4,Gly-ol5]enkephalin and dermorphin had affinities of 1.39 and 1.22 nM for mu-receptors and 355.8 and 178.6 nM for delta-receptors, respectively. Affinities of dimeric-dermorphin0 for mu- and delta-receptors, and the mu-selectivity ratio, exceeded values characteristic of dermorphin. The dimerized amino-terminal dermorphin analogues are peptides whose receptor binding differed from the parent molecule; e.g. the affinity of dimeric tetrapeptides toward mu-receptors was reduced but was increased for delta-receptors relative to monomeric dermorphin-(1-4)-amide. Dimeric tetradermorphin linked by a bridge containing 12 methylene units (di-tetra-dermorphin12), exhibited a dramatic loss in the mu-selectivity ratio as a result of diminished mu-affinity. On the other hand, substitution of Gly4 by Sar in di-tetra-dermorphin2 enhanced binding to mu-receptors: substitution of D-Arg2 for D-Ala resulted in an increased binding to mu-receptors while decreasing binding to delta-receptors, yielding a peptide with the highest mu-selectivity ratio. These substitutions of D-Arg2 and Sar4 in dimeric amino-terminal dermorphin pentapeptides enhanced binding to both mu- and delta-receptors relative to dermorphin-(1-5)-amide, but led to a decrease in its mu-selectivity ratio. Several dimeric dermorphin analogues exhibited an enhanced mu-selectivity ratio relative to their monomeric analogues. Dimeric peptides, which had a relatively high affinity for mu-receptors, were effective in the suppression of gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562839

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

2.  Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1).

Authors:  Gianfranco Balboni; Remo Guerrini; Severo Salvadori; Lucia Negri; Elisa Giannini; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus
Journal:  J Med Chem       Date:  2005-12-29       Impact factor: 7.446

Review 3.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

4.  Novel multiple opioid ligands based on 4-aminobenzazepinone (Aba), azepinoindole (Aia) and tetrahydroisoquinoline (Tic) scaffolds.

Authors:  Steven Ballet; Ewa D Marczak; Debby Feytens; Severo Salvadori; Yusuke Sasaki; Andrew D Abell; Lawrence H Lazarus; Gianfranco Balboni; Dirk Tourwé
Journal:  Bioorg Med Chem Lett       Date:  2010-01-20       Impact factor: 2.823

5.  Inhibition of the development of morphine tolerance by a potent dual mu-delta-opioid antagonist, H-Dmt-Tic-Lys-NH-CH2-Ph.

Authors:  Yunden Jinsmaa; Ewa D Marczak; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

6.  Prerequisite for His(4) in deltorphin A for highδ opioid receptor selectivity.

Authors:  S Salvadori; R Guerrini; V Forlani; S D Bryant; M Attila; L H Lazarus
Journal:  Amino Acids       Date:  1994-10       Impact factor: 3.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.